



#### PRESENTATION

- Private biotech company in San Francisco developing first/best-in-class pharmaceutical assets
- Founded and managed by proven industry executives. Track record of excelling delivering multi B \$ exits
- Novartis, Astellas, Pfizer/Pharmacia, IVAX, Pharmacyclics

#### MISSION

- Accelerating Wound/Tissue Healing
- Preventing Scarring & Long COVID

#### PROPRIETARY TECHNOLOGY

CELLEXA™ platform: Encoded gene vector enabling endogenous (“in the human body”) production of a multipotent peptide (ensereptide or long half-life analogues thereof).

#### TARGET INDICATIONS

VIRLEXA™ - Gene vector inhaled once + one intramuscular injection

##### Prevention of lung scarring safer

- Respiratory infections (COVID-19, RSV)
- Prevention of hospitalization, death and Long COVID after positive COVID test

SCARLEXA™ – Gene vector injection into or under the skin (intramuscular)

##### Prevention of scarring after:

- surgery
- Burns ((skin cell suspension)

#### UNMET NEEDS

- Long COVID in more than 20 percent of COVID patients – no effective treatment
- There are no pharmaceutical products available on the market to prevent adhesions and scars
- Globally epidemic increase of burn injuries

#### DEVELOPMENT TIMELINE

Preclin./Manufacturing/IND: 12+ mos.  
Clinical Phase 1-2, and 3: 24-36+ mos.

#### FUNDING Series A +B+C (\$M)

- VIRLEXA: 9+9+9  
Prevent Long COVID
- SCARLEXA: 18+18+18  
Prevent scarring  
After surgery

#### MARKET POTENTIAL

- Long Covid 500 M - .5 B year 5
- Post-operative scarring multibillion dollar market

#### CONTACT

201 Spear St, Suite 1100 San Francisco, CA 94105 Phone 1-510-499-6376  
www.Cellastra.com

[Karl.Mettinger@cellastra.com](mailto:Karl.Mettinger@cellastra.com)

## VIRLEXA™

## GENE VECTOR FOR PREVENTION OF LONG COVID -

## Joint Venture Opportunity – “The \$3.5 T Challenge”

#### RECENT NEWS

April 02, 2022 **Cellastra announces update on Pipeline, Promotions and development Plans**

- Shareholders Meeting voted in favor of increasing maximum allowed shares from 10 million to 100 Million
- Two industry veterans promoted to Executive Vice Presidents
- Announces the CELLEXA™ Platform with a library of encoded gene vectors including Virlexa™ and Scarlexa™

#### MARKET & INTRODUCTION

- Prevalence and Incidence of Long COVID
- US: current prevalence is between 9- 10 million cases  
As of (1/15/2022 the cumulative number of deaths in COVID-19 are about 1 million (CDC) and the cumulative number of Long COVID 10 x higher, thus about 10 million. With only about 25% recover by the end of 12 months (Evans 2022) follow up and other symptoms may increase by 24 months follow up
- **Globally: Current prevalence is about 120 million cases**  
600 million confirmed cases of COVID have been registered (WHO), and an estimated 20 percent may have developed Long COVID.
- **Projections Globally 2023-2033: 25-50 million new cases of Long COVID annually**  
An estimated 450 million new COVID cases annually (based on statistics for 2022)  
It is projected that COVID will remain a continued public health concern enquiring annual vaccinations just like influenza. Omicron variants are reported to be less severe but more contagious and thus have a higher incidence than previous variants but a 50 percent lower incidence of Long COVID.  
A conservative projection is based on 10 percent of 250an estimated M-500M new COVID cases annually (assuming similar to influenza recurrence).

e

**BENEFITS:** VIRLEXA™: One inhalation combined with one intramuscular injection administered in newly diagnosed COVID patients may help prevent hospitalization, death and Long COVID ([See rationale next page](#))

#### DEVELOPMENT TO DATE / COLLABORATORS

- Genevector covered by patent licenced from Guelph University and Cellastra patent filing covering broad range of vectors and proprietary peptides
- A complete “turn-key” development package including exclusive rights to patents, development rights and marketing in North America or Worldwide OR Joint Venture with option for buy-out

#### EXECUTIVE TEAM

- **Karl Mettinger, MD, PhD, President & CEO**, 35+ yrs, incl. Karolinska Institute, Kabi/Pharmacia, IVAX, Supergen, Oncolytics, Pharmacyclics, 3 Three Multi \$B Exits. Founding President Swedish Stroke Society with 10,000 members
- **Vinod Kumar, MD, CMO, EVP**, 30 years exp from U. Illinois, U Miami, Lilly, and Novartis (section Head/Global Program Medical Director)
- **Henrik (Hank) Kulmala, PhD, EVP Product Development /Regulatory**, 35+ years prev. exp incl Marion Merrell Dow, Fujisawa, Genix, 75 drugs (INDs, NDAs, BLAs)
- **Brad Thompson, PhD, Chair, CTO**, 35+ years, incl BIOTEC Canada, CEO Oncolytics, Avomed, Kickshaw Ventures, Inventor of several gene therapy patents
- **Sven Andreasson, Vice-Chair**, 35+ yrs, Kabi, Pharmacia (Acquired by Pfizer for \$60B), NovaVax
- **Daniel Quintero, Esq, General Counsel, Secretary**, 20+ years, incl Founding Partner Prometheus Partners LLP, Sony Optiarch / Electronics
- **Bruce Phillips, CPA, CFO**, 30+years exp incl Arthur Young, HPC, Xero, Aprio
- **Kent Persson, PhD, Cofounder**, 20+ years, incl UCSF, Bio-Rad, Octapharma

#### SCIENTIFIC ADVISORY BOARD

- **Sarah Wootton, PhD, Associate Professor, Dept. Pathophysiology, Ontario Veterinary College and University of Guelph, Ontario**
- **Christopher H Evans, PhD, Professor, Mayo Clinic**, Director Rehabilitation Medicine Research Center, Prev prof. Harvard, > 300 publications, recent review of new treatment modalities for tendon injuries.
- **Folke Sjoberg, MD, PhD**, Professor of Burn Surgery, Depts. of Hand, Plastic Surgery Linköping University Hospital, Sweden, past President of the European Burns Association, and program chair International Society f. Burn Injuries
- **Magda Forsberg, PhD**, Karolinska Institute, CEO Device company DVL-Op


# Turning the Lung Into a Temporary Bioreactor

- Total lung epithelial surface area
- = 100 sqm (as a small raquet ball court)
- One inhalation enables expression of peptides for the 30 day life cycle of the lung epithelial cells
- Vector may bind to the ACE-2 receptors for COVID and block further infection

+One intramuscular Injection may express systemic levels of peptide for many months



## Enseptide Anti-COVID-19 Mechanisms



Enseptide = PXL01

*Nilsson E et al, Ann Surg . 2009,250(6):1021-8.*

